Infliximab and Tofacitinib Attenuate Neutralizing Antibody Responses Against SARS-CoV-2 Ancestral and Omicron Variants in Inflammatory Bowel Disease Patients Following 3 Doses of COVID-19 Vaccine.

Liu, Zhigang; Alexander, James L; Lin, Kathy Weitung; Ahmad, Tariq; Pollock, Katrina M; Powell, Nick

Liu, Zhigang; Alexander, James L; Lin, Kathy Weitung; Ahmad, Tariq; Pollock, Katrina M; Powell, Nick.

Liu Z; Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, London, United Kingdom.
Alexander JL; Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, London, United Kingdom, and, Department of Gastroenterology, Imperial College Healthcare NHS Trust, London, United Kingdom.
Lin KW; Department of Infectious Disease, Faculty of Medicine, Imperial College London, London, United Kingdom.
Ahmad T; Royal Devon University Healthcare NHS Foundation Trust, Exeter, United Kingdom.
Pollock KM; Department of Infectious Disease, Faculty of Medicine, Imperial College London, London, United Kingdom.
Powell N; Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, London, United Kingdom, and, Department of Gastroenterology, Imperial College Healthcare NHS Trust, London, United Kingdom. Electronic address: npowell@imperial.ac.uk.

Gastroenterology ; 2022 Oct 19.

Artículo en Inglés | MEDLINE | ID: covidwho-2232653

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: Disponible Colección: Bases de datos internacionales Base de datos: MEDLINE Tópicos: Vacunas / Variantes Idioma: Inglés Año: 2022 Tipo del documento: Artículo País de afiliación: J.gastro.2022.10.010

Similares

MEDLINE

LILACS

LIS

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google